PD-1/PD-L1 blockade as part of combination strategies toward functional cure of chronic hepatitis B - Takeaways - MDSpire

PD-1/PD-L1 blockade as part of combination strategies toward functional cure of chronic hepatitis B

  • By

  • Mei Li

  • Dandan Feng

  • Juanjuan Shi

  • Shuangsuo Dang

  • Xiaoli Jia

  • Wenjun Wang

  • July 9, 2026

  • 0 min

Share

  • 1

    Chronic hepatitis B (CHB) affects approximately 260 million people globally and remains a leading cause of cirrhosis and hepatocellular carcinoma.

  • 2

    Functional cure in CHB is defined as sustained loss of hepatitis B surface antigen (HBsAg) and durable viral control after treatment cessation.

  • 3

    PD-1/PD-L1 inhibitors have shown promise in reducing HBsAg levels and achieving functional cure, especially in patients with low baseline HBsAg.

  • 4

    Combining PD-1/PD-L1 blockade with pegylated interferon has resulted in a functional cure rate of 30% in certain patient subsets.

  • 5

    Challenges remain in optimizing dosing, selecting patients, and managing immune-related adverse events for PD-1/PD-L1 combination therapies.

Original Source(s)

PD-1/PD-L1 blockade as part of combination strategies toward functional cure of chronic hepatitis B

  • by Mei Li, Dandan Feng, Juanjuan Shi, Shuangsuo Dang, Xiaoli Jia, Wenjun Wang

  • July 9, 2026

Related Content

Osteoarthritis as a systemic disorder: multi-organ crosstalk in pathogenesis and therapeutic targeting

Etiology, diagnosis, and management of chronic pancreatitis associated primary complications: a narrative review

Editorial: AI-driven smart sensing and processing for personalized healthcare